Tiago Fauth
Stock Analyst at Wells Fargo
(2.36)
# 2,617
Out of 4,981 analysts
153
Total ratings
42.98%
Success rate
-0.63%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $6.97 | +158.25% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $403.11 | +2.70% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $5.38 | +85.87% | 2 | Sep 3, 2025 | |
| INSM Insmed | Maintains: Overweight | $140 → $171 | $143.14 | +19.46% | 8 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $58.98 | +23.77% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $26.77 | +15.80% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $461.14 | -14.34% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $29.00 | +124.14% | 8 | Jul 10, 2025 | |
| VRNA Verona Pharma | Downgrades: Equal-Weight | $138 → $107 | $106.37 | +0.59% | 7 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $51.47 | +47.66% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $3.61 | +94.17% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $16.59 | +508.80% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.53 | +96.08% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $15.55 | +67.20% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $7.73 | +119.92% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $59.90 | +25.21% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $2.30 | +2,595.65% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $194.62 | -54.27% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $18.01 | +183.18% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $53.14 | +125.82% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $15.51 | -74.20% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.62 | +434.35% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $8.21 | +216.69% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $4.35 | +543.68% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $24.39 | +232.10% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.69 | +1,051.24% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.90 | +636.84% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.05 | +3,138.10% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $2.83 | +5,200.35% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $39.01 | -25.66% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.61 | +707.45% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.67 | +386.89% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.23 | +62.60% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $756.83 | -55.08% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $274.40 | -5.61% | 1 | Apr 28, 2021 |
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $6.97
Upside: +158.25%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $403.11
Upside: +2.70%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $5.38
Upside: +85.87%
Insmed
Sep 3, 2025
Maintains: Overweight
Price Target: $140 → $171
Current: $143.14
Upside: +19.46%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $58.98
Upside: +23.77%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $26.77
Upside: +15.80%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $461.14
Upside: -14.34%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $29.00
Upside: +124.14%
Verona Pharma
Jul 10, 2025
Downgrades: Equal-Weight
Price Target: $138 → $107
Current: $106.37
Upside: +0.59%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $51.47
Upside: +47.66%
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $3.61
Upside: +94.17%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $16.59
Upside: +508.80%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.53
Upside: +96.08%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $15.55
Upside: +67.20%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $7.73
Upside: +119.92%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $59.90
Upside: +25.21%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $2.30
Upside: +2,595.65%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $194.62
Upside: -54.27%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $18.01
Upside: +183.18%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $53.14
Upside: +125.82%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $15.51
Upside: -74.20%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.62
Upside: +434.35%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $8.21
Upside: +216.69%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $4.35
Upside: +543.68%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $24.39
Upside: +232.10%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.69
Upside: +1,051.24%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.90
Upside: +636.84%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.05
Upside: +3,138.10%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $2.83
Upside: +5,200.35%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $39.01
Upside: -25.66%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.61
Upside: +707.45%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.67
Upside: +386.89%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.23
Upside: +62.60%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $756.83
Upside: -55.08%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $274.40
Upside: -5.61%